Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,128,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the transaction, the chief operating officer now directly owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. The trade was a 12.01 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Trading Down 0.4 %

Shares of ROIV stock opened at $11.17 on Friday. The stock has a market cap of $8.13 billion, a price-to-earnings ratio of 1.98 and a beta of 1.27. The stock has a 50-day moving average of $11.74 and a 200-day moving average of $11.60. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences during the third quarter worth $35,000. US Bancorp DE grew its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after acquiring an additional 1,948 shares during the period. Point72 Hong Kong Ltd acquired a new stake in Roivant Sciences during the second quarter worth approximately $36,000. GAMMA Investing LLC grew its stake in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. Finally, Quarry LP acquired a new stake in Roivant Sciences during the second quarter worth approximately $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.